9P Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase

E Lee,R Papp,E Fontana,S May,L Carter,T.A Yap,A.J Fretland,D Ulanet,Rachel M Mcdougall ,S Patel,P Manley,Ezra Y Rosen ,Ruth Plummer ,S Lheureux,M Koehler,David R Spigel ,P Nejad,M Wainszelbaum,Niharika B Mettu ,Martin Højgaard

doi:10.1016/j.annonc.2022.01.072

9P Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase

E Lee, R Papp + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.01.072

Copy DOI

Journal: Annals of Oncology	Publication Date: Mar 1, 2022
License type: publisher-specific-oa

Affiliation: Dana-Farber Cancer Institute, Sarah Cannon, The Christie NHS Foundation Trust, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Duke Medical Center, Rigshospitalet

#Ataxia Telangiectasia And Rad3-related #Assessment Of QT + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

RP-3500 is an oral inhibitor of ATR (ATRi) in development for the treatment of patients (pts) with advanced solid tumors carrying alterations in ATRi-sensitizing genes. We report popPK co-variates and effect on QT prolongation in 120 pts treated with RP-3500 in the phase 1 TRESR study (NCT04497116).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.